203 related articles for article (PubMed ID: 21572547)
1. Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status.
Lee JK; Chan AT
Curr Colorectal Cancer Rep; 2011 Jun; 7(2):136-144. PubMed ID: 21572547
[TBL] [Abstract][Full Text] [Related]
2. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
[TBL] [Abstract][Full Text] [Related]
3. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
Vodenkova S; Buchler T; Cervena K; Veskrnova V; Vodicka P; Vymetalkova V
Pharmacol Ther; 2020 Feb; 206():107447. PubMed ID: 31756363
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
[TBL] [Abstract][Full Text] [Related]
6. Predictive markers for colorectal cancer: current status and future prospects.
Longley DB; McDermott U; Johnston PG
Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
8. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
9. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
To KK; Tong CW; Wu M; Cho WC
World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.
Takahashi M; Cuatrecasas M; Balaguer F; Hur K; Toiyama Y; Castells A; Boland CR; Goel A
PLoS One; 2012; 7(10):e46684. PubMed ID: 23056401
[TBL] [Abstract][Full Text] [Related]
12. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
13. Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options.
Rodrigues D; Longatto-Filho A; Martins SF
Biomed Res Int; 2016; 2016():6896024. PubMed ID: 27563673
[TBL] [Abstract][Full Text] [Related]
14. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.
Zarour LR; Anand S; Billingsley KG; Bisson WH; Cercek A; Clarke MF; Coussens LM; Gast CE; Geltzeiler CB; Hansen L; Kelley KA; Lopez CD; Rana SR; Ruhl R; Tsikitis VL; Vaccaro GM; Wong MH; Mayo SC
Cell Mol Gastroenterol Hepatol; 2017 Mar; 3(2):163-173. PubMed ID: 28275683
[TBL] [Abstract][Full Text] [Related]
15. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
Koopman M; Venderbosch S; Nagtegaal ID; van Krieken JH; Punt CJ
Eur J Cancer; 2009 Jul; 45(11):1935-49. PubMed ID: 19473832
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
17. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
18. Novel biomarkers for the diagnosis and prognosis of colorectal cancer.
Oh HH; Joo YE
Intest Res; 2020 Apr; 18(2):168-183. PubMed ID: 31766836
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges.
Koncina E; Haan S; Rauh S; Letellier E
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32019056
[TBL] [Abstract][Full Text] [Related]
20. RNA biomarkers in colorectal cancer.
Bustin SA; Murphy J
Methods; 2013 Jan; 59(1):116-25. PubMed ID: 23079397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
